NJ-RUNPOD
8.5.2024 15:08:27 CEST | Business Wire | Press release
RunPod, the launchpad that empowers developers to deploy custom full-stack AI applications, today announced it raised $20M in Seed funding, co-led by Intel Capital and Dell Technologies Capital with participation from Julien Chaummond, Nat Friedman, and Adam Lewis. In conjunction with the financing, Mark Rostick, Vice President and Senior Managing Director at Intel Capital, will join RunPod’s board of directors.
RunPod is a globally distributed GPU cloud computing service for training, deploying, and scaling AI models. Using RunPod’s two core products, GPU Cloud and Serverless, developers can spin up an on-demand GPU instance in a few clicks and create autoscaling API endpoints for scaling inference on AI models in production.
“The ability to create and deploy AI applications at scale will be paramount to their adoption and utilization,” said Amjad Masad, RunPod investor. “The RunPod team has clearly prioritized the developer experience to create an elegant solution that enables individuals to rapidly develop custom AI apps or integrations while also paving the way for organizations to truly deliver on the promise of AI.”
RunPod makes it simple for developers to seamlessly run any GPU workload, allowing them to focus less on Machine Learning operations and more on building their applications. These capabilities have proven advantageous to developers and resulted in RunPod’s swift expansion with 10-fold revenue growth year over year.
“RunPod started as a playground for developers and innovators, a place where they went to do their research, develop and finetune their projects; now, it boasts a community of over 100K developers,” said Zhen Lu, co-founder and CEO of RunPod. “We’ve grown so quickly because RunPod strikes the perfect balance between providing developers with the freedom to launch whatever they want, while still having the necessary infrastructure and tools in place to assist in the customization, development, and deployment of differentiated products.”
The emergence of AI-specific workloads has given rise to increased computational demands. Once the go-to solution, out-of-the-box cloud infrastructure platforms are no longer cost-effective or fast enough to create custom-differentiated products. With RunPod, developers can reliably and simply develop, train, scale, and launch custom full-stack AI applications or integrations in the cloud on a global scale.
“RunPod is rapidly growing both its customer base and revenue by offering a broad, fast, and easy-to-use platform that meets the needs of developers and their model-based applications," said Mark Rostick, Vice President and Senior Managing Partner at Intel Capital. “I’ve watched RunPod’s momentum scale from a small startup offering individual developers an ecosystem to kickstart their research and development to a serverless offering that allows enterprise customers to scale their customized high-grade products and solutions.”
Rapid growth and developer adoption created the need to grow the team almost 10x in the past year, establishing itself as a leader pioneering GPU AI-powered transformation. The platform has recently launched the ability to deploy CPU compute instances, a huge milestone in creating a holistic cloud solution. This Seed funding will enable RunPod to enhance the day-to-day life of developers, form new partnerships and integrations for seamless user experiences, and offer new and existing customers the perfect foundation for developing custom AI models.
“As the enterprise deploys more AI applications into production, the key to their success is access to fast, reliable, and scalable infrastructure. This is what Zhen, Pardeep, and the team have built with the RunPod platform,” said Radhika Malik, Partner at Dell Technologies Capital. “They are committed to keeping the dev experience central to everything they do. That’s resulted in overwhelmingly positive sentiment from the community and impressive, sustained user growth.”
About RunPod:
RunPod is a globally distributed GPU cloud platform that empowers developers to deploy custom full-stack AI applications – simply, globally, and at scale. With RunPod’s key offerings, GPU Instances and Serverless GPUs, developers can develop, train and scale AI applications in one cloud within seconds. RunPod is committed to making cloud computing accessible and affordable without compromising features, usability, or experience. It strives to empower individuals and enterprises with cutting-edge technology, enabling them to unlock the potential of AI and cloud computing. To learn more about RunPod, visit https://www.runpod.io/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508053225/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
